The global competent cells market is set to experience substantial growth, projected to reach a valuation of USD 5.9 billion by 2032 from USD 2.1 billion in 2022, expanding at a robust CAGR of 11.1% during the forecast period. Key factors driving market expansion include increased demand for chemically competent cells and advancements in biotechnological research.
Competent cells refer to bacterial cells that possess the ability to take up foreign DNA from their environment via a mechanism called transformation. This phenomenon was first described by Griffith in the context of Streptococcus pneumoniae. When the cell walls of E. coli are modified, these cells exhibit an increased propensity to absorb DNA. The treatment with calcium chloride and exposure to temperature shock can enhance the competency of the cells. Additionally, cells that are in a state of rapid growth tend to be more competent compared to those in other developmental stages.
Key Takeaways
- Market Size and Growth: The competent cells market was valued at approximately US$ 2.1 billion in 2022 and is expected to reach US$ 5.9 billion by 2032, driven by advancements in molecular cloning and biotechnology applications.
- Product Segmentation: Chemically competent cells dominated the market in 2021, holding a substantial share of 67.8% due to their high transformation efficiency and ease of use.
- Regional Insights: North America is currently the leading region, accounting for a significant portion of the market share, followed by Europe and Asia-Pacific, where rapid advancements in biotechnology are fostering growth.
- Application Areas: The primary applications of competent cells include cloning, protein expression, and mutagenesis, with increasing utilization in personalized medicine and recombinant protein production.
- Market Drivers: Key factors propelling market growth include rising government funding for life sciences research, increased focus on rare disease studies, and the growing biotechnology workforce.
Key Market Insights and Highlights:
- Impressive Market Growth:
- The competent cells market is expected to grow at a double-digit CAGR of 11.1% from 2022 to 2032, driven by advancements in genetic engineering and biotechnology sectors.
- Rising applications in academic research, pharmaceutical R&D, and molecular cloning are major contributors to this growth.
- Dominance of Chemically Competent Cells:
- Chemically competent cells commanded the largest market share, accounting for approximately 67.8% in 2021. Their popularity stems from their efficiency in gene transformation and ease of use in laboratory settings.
- Continuous innovations in the production of chemically competent cells are anticipated to maintain their dominance over the forecast period.
- Increasing Biotechnology Applications:
- The growing field of biotechnology, including the development of recombinant proteins and gene therapy products, is expanding the use of competent cells.
- Additionally, the demand for cloning and subcloning applications in molecular biology and genetic engineering supports the robust growth of this market.
- Regional Market Dynamics:
- North America holds a significant market share due to the high concentration of biotechnology companies and research institutions.
- Emerging markets in Asia-Pacific are expected to witness accelerated growth, fueled by increasing investments in biotechnology research and favorable regulatory frameworks.
Market Outlook:
The competent cells market is poised for steady growth as demand for advanced molecular biology applications continues to rise globally. The expanding scope of gene cloning, protein expression, and gene therapy is expected to support sustained investment and development in the sector.
Competitive Landscape
With several competitors in the competent cells market, the overall market is fragmented. To expand their customer base, leading companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
For instance:
- The VmaxTM X2 Competent Cells were introduced in January 2020 by SGI-DNA, the company behind the BioXpTM 3200 System and Gibson Assembly® Reagents. They are intended to produce two to four times as much soluble protein in half the time as current methods that rely on E. coli.
- Bluebird Bio announced the introduction of ZYNTEGLOTM Gene Therapy for Patients with Transfusion-Dependent -Thalassemia Who Do Not Have β?/β0 Genotype in Germany in January 2020.
A Full Report Overview
Key Companies Profiled
- Agilent Technologies Inc.
- Genescript Biotech Corporation
- Bio-Rad Laboratories Inc
- Merck & Co Inc
- OriGene Technologies, Inc
- New England Biolabs Inc
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.,
- QIAGEN N.V.,
- Zymo Research Corporation
- Promega Corporation
- HiMedia Laboratories
- Avantor, Inc.
- Scarab Genomics, LLC
- Lucigen
- bluebird bio, Inc.
- Tonbo Biosciences
- TransGen Biotech
- Codex DNA, Inc.
Key Market Segments Covered in Competent Cells Industry Research
By Product:
- Chemically Competent Cells
- Electrocompetent Cells
By Application:
- Cloning
- Protein Expression
- Other Applications
By End User:
- Academic Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube